---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-001752"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T11:48:46.860344+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aclaris Q4 net loss improves to $1.5M on $17.6M revenue; cash down to $181.9M

## Summary
- Net loss $1.5M vs $27.6M YoY; revenue $17.6M vs $7.8M driven by Sun Pharma upfront payment.
- Full-year net loss $88.5M; cash & securities $181.9M (Dec 2023) vs $229.8M (Dec 2022).
- Impairment charge of $6.6M on IPR&D asset after discontinuing an immuno-inflammatory drug candidate.
- Positive Phase 2b top-line for ATI-1777 in atopic dermatitis; seeking a partner for development/commercialization.
- Co-founder Dr. Neal Walker returns as Interim CEO; company to advance zunsemetinib in oncology via Washington University trials.

## SEC filing metadata
- accession: 0001558370-24-001752
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837024001752/0001558370-24-001752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837024001752/acrs-20240227x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-001752
- JSON: https://secwatch.observer/filing/0001558370-24-001752.json
- Plain text: https://secwatch.observer/filing/0001558370-24-001752.txt

## Key facts
- Earnings Releases
  Aclaris Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022., net income Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022. ... N.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: Total revenue was $17.6 million for the fourth quarter of 2023 compared to $7.8 million for the fourth quarter of 2022.
  - Net income: Net loss was $1.5 million for the fourth quarter of 2023 compared to $27.6 million for the fourth quarter of 2022. ... N
  - Result: reported results
  source text: Aclaris Therapeutics, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1557746/000155837024001752/0001558370-24-001752-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.